FDA approves Alzheimer's drug from Biogen, against experts' advice
Published
The approval comes after an independent panel to the FDA urged the agency to reject the drug, which will be sold under the name Aduhelm.
Full ArticlePublished
The approval comes after an independent panel to the FDA urged the agency to reject the drug, which will be sold under the name Aduhelm.
Full ArticleThe FDA’s controversial approval of a Biogen drug for Alzheimer’s disease could blunt future R&D, experts warn.
Watch VideoGovernment health officials on Monday approved the first new drug for Alzheimer's disease in nearly 20 years,..